Molecular determinants of agonist and antagonist signaling through the IL-36 receptor

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 921-930

  Günther, Sebastian ^a   Sundberg, Eric J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 36 GAMMA; INTERLEUKIN 36 RECEPTOR; INTERLEUKIN 36 RECEPTOR AGONIST; INTERLEUKIN 36 RECEPTOR ANTAGONIST; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOPHYSICS; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PUSTULAR PSORIASIS; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; INTERLEUKIN-1; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84904264198     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400538     Document Type: Article

References (43)

1. Lomedico, P. T., U. Gubler, C. P. Hellmann, M. Dukovich, J. G. Giri, Y. C. Pan, K. Collier, R. Semionow, A. O. Chua, and S. B. Mizel. 1984. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312: 458-462.
2. Auron, P. E., A. C. Webb, L. J. Rosenwasser, S. F. Mucci, A. Rich, S. M. Wolff, and C. A. Dinarello. 1984. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. USA 81: 7907-7911. (Pubitemid 15169171)
3. Dinarello, C. A., A. Simon, and J. W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11: 633-652.
4. Dinarello, C. A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27: 519-550.
5. van de Veerdonk, F. L., A. K. Stoeckman, G. Wu, A. N. Boeckermann, T. Azam, M. G. Netea, L. A. Joosten, J. W. van der Meer, R. Hao, V. Kalabokis, and C. A. Dinarello. 2012. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. USA 109: 3001-3005.
6. O'Neill, L. A. 2008. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226: 10-18.
7. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10: 89-102.
8. Towne, J. E., B. R. Renshaw, J. Douangpanya, B. P. Lipsky, M. Shen, C. A. Gabel, and J. E. Sims. 2011. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286: 42594-42602.
9. Vigne, S., G. Palmer, C. Lamacchia, P. Martin, D. Talabot-Ayer, E. Rodriguez, F. Ronchi, F. Sallusto, H. Dinh, J. E. Sims, and C. Gabay. 2011. IL-36R ligands are potent regulators of dendritic and T cells. Blood 118: 5813-5823.
10. Mutamba, S., A. Allison, Y. Mahida, P. Barrow, and N. Foster. 2012. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 42: 607-617.
11. + T cells. Blood 120: 3478-3487.
12. Hou, J., S. A. Townson, J. T. Kovalchin, A. Masci, O. Kiner, Y. Shu, B. M. King, E. Schirmer, K. Golden, C. Thomas, et al. 2013. Design of a superior cytokine antagonist for topical ophthalmic use. Proc. Natl. Acad. Sci. USA 110: 3913-3918.
13. Blumberg, H., H. Dinh, E. S. Trueblood, J. Pretorius, D. Kugler, N. Weng, S. T. Kanaly, J. E. Towne, C. R. Willis, M. K. Kuechle, et al. 2007. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204: 2603-2614. (Pubitemid 350044786)
14. Tortola, L., E. Rosenwald, B. Abel, H. Blumberg, M. Schäfer, A. J. Coyle, J. C. Renauld, S. Werner, J. Kisielow, and M. Kopf. 2012. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 122: 3965-3976.
15. Debets, R., J. C. Timans, B. Homey, S. Zurawski, T. R. Sana, S. Lo, J. Wagner, G. Edwards, T. Clifford, S. Menon, et al. 2001. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167: 1440-1446. (Pubitemid 32703142)
16. Zhou, X., J. G. Krueger, M. C. Kao, E. Lee, F. Du, A. Menter, W. H. Wong, and A. M. Bowcock. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics 13: 69-78. (Pubitemid 37129170)
17. Marrakchi, S., P. Guigue, B. R. Renshaw, A. Puel, X. Y. Pei, S. Fraitag, J. Zribi, E. Bal, C. Cluzeau, M. Chrabieh, et al. 2011. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365: 620-628.
18. Onoufriadis, A., M. A. Simpson, A. E. Pink, P. Di Meglio, C. H. Smith, V. Pullabhatla, J. Knight, S. L. Spain, F. O. Nestle, A. D. Burden, et al. 2011. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89: 432-437.
19. Ramadas, R. A., S. L. Ewart, Y. Iwakura, B. D. Medoff, and A. M. LeVine. 2012. IL-36α exerts pro-inflammatory effects in the lungs of mice. PLoS ONE 7: e45784.
20. Thomas, C., J. F. Bazan, and K. C. Garcia. 2012. Structure of the activating IL-1 receptor signaling complex. Nat. Struct. Mol. Biol. 19: 455-457.
21. Wang, D., S. Zhang, L. Li, X. Liu, K. Mei, and X. Wang. 2010. Structural insights into the assembly and activation of IL-1β with its receptors. Nat. Immunol. 11: 905-911.
22. Towne, J. E., K. E. Garka, B. R. Renshaw, G. D. Virca, and J. E. Sims. 2004. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kB and MAPKs. J. Biol. Chem. 279: 13677-13688. (Pubitemid 38468896)
23. Dunn, E. F., N. J. Gay, A. F. Bristow, D. P. Gearing, L. A. O'Neill, and X. Y. Pei. 2003. High-resolution structure of murine interleukin 1 homologue IL-1F5 reveals unique loop conformations for receptor binding specificity. Biochemistry 42: 10938-10944. (Pubitemid 37174384)
24. Li, C., A. Wen, B. Shen, J. Lu, Y. Huang, and Y. Chang. 2011. FastCloning: a highly simplified, purification-free, sequence- and ligation-independent PCR cloning method. BMC Biotechnol. 11: 92.
25. Huang, J., X. Gao, S. Li, and Z. Cao. 1997. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc. Natl. Acad. Sci. USA 94: 12829-12832. (Pubitemid 27518436)
26. Kabsch, W. 2010. XDS. Acta Crystallogr. D Biol. Crystallogr. 66: 125-132.
27. Evans, P. R., and G. N. Murshudov. 2013. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69: 1204-1214.
28. McCoy, A. J., R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read. 2007. Phaser crystallographic software. J. Appl. Cryst. 40: 658-674. (Pubitemid 47080256)
29. Adams, P. D., P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66: 213-221.
30. Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66: 486-501.
31. Ju, G., E. Labriola-Tompkins, C. A. Campen, W. R. Benjamin, J. Karas, J. Plocinski, D. Biondi, K. L. Kaffka, P. L. Kilian, S. P. Eisenberg, et al. 1991. Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc. Natl. Acad. Sci. USA 88: 2658-2662. (Pubitemid 21916477)
32. Greenfeder, S. A., T. Varnell, G. Powers, K. Lombard-Gillooly, D. Shuster, K. W. McIntyre, D. E. Ryan, W. Levin, V. Madison, and G. Ju. 1995. Insertion of a structural domain of interleukin (IL)-1β confers agonist activity to the IL-1 receptor antagonist. Implications for IL-1 bioactivity. J. Biol. Chem. 270: 22460-22466.
33. Liu, X., M. Hammel, Y. He, J. A. Tainer, U. S. Jeng, L. Zhang, S. Wang, and X. Wang. 2013. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl. Acad. Sci. USA 110: 14918-14923.
34. Vigers, G. P., D. J. Dripps, C. K. Edwards, III, and B. J. Brandhuber. 2000. X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J. Biol. Chem. 275: 36927-36933. (Pubitemid 32002106)
35. Eswar, N., B. John, N. Mirkovic, A. Fiser, V. A. Ilyin, U. Pieper, A. C. Stuart, M. A. Marti-Renom, M. S. Madhusudhan, B. Yerkovich, and A. Sali. 2003. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 31: 3375-3380. (Pubitemid 37442163)
36. Schreuder, H., C. Tardif, S. Trump-Kallmeyer, A. Soffientini, E. Sarubbi, A. Akeson, T. Bowlin, S. Yanofsky, and R. W. Barrett. 1997. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386: 194-200. (Pubitemid 27131449)
37. Vigers, G. P., L. J. Anderson, P. Caffes, and B. J. Brandhuber. 1997. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β. Nature 386: 190-194. (Pubitemid 27131448)
38. Navarini, A. A., L. Valeyrie-Allanore, N. Setta-Kaffetzi, J. N. Barker, F. Capon, D. Creamer, J. C. Roujeau, P. Sekula, M. A. Simpson, R. C. Trembath, et al. 2013. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J. Invest. Dermatol. 133: 1904-1907.
39. Setta-Kaffetzi, N., A. A. Navarini, V. M. Patel, V. Pullabhatla, A. E. Pink, S. E. Choon, M. A. Allen, A. D. Burden, C. E. Griffiths, M. M. Seyger, et al. 2013. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J. Invest. Dermatol. 133: 1366-1369.
40. Li, M., J. Han, Z. Lu, H. Li, K. Zhu, R. Cheng, Q. Jiao, C. Zhang, C. Zhu, Y. Zhuang, et al. 2013. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J. Invest. Dermatol. 133: 2637-2639.
41. Körber, A., R. Mössner, R. Renner, H. Sticht, D. Wilsmann-Theis, P. Schulz, M. Sticherling, H. Traupe, and U. Hüffmeier. 2013. Mutations in IL36RN in patients with generalized pustular psoriasis. J. Invest. Dermatol. 133: 2634-2637.
42. Kanazawa, N., T. Nakamura, N. Mikita, and F. Furukawa. 2013. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J. Dermatol. 40: 749-751.
43. Farooq, M., H. Nakai, A. Fujimoto, H. Fujikawa, A. Matsuyama, N. Kariya, A. Aizawa, H. Fujiwara, M. Ito, and Y. Shimomura. 2013. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum. Mutat. 34: 176-183.